TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS

This disclosure provides compounds of Formula (I) (e.g., (I-A) (e.g., (I-A-1), (I-A-2), or (I-A-3)), (I-B) (e.g., (I-B-1), (I-B-2), or (I-B-3)), (I-C), (I-D), (I-E) (e.g., (I-E-1), (I-E-2), or (I-E-3)), (I-Ea) (e.g., (I-Ea-1), (I-Ea-2), or (I-Ea-3)), (I-Eb) (e.g., (I-Eb-1), (I-Eb-2), or (I-Eb-3)), (I-F) (e.g., (I-F-1), (I-F-2), or (I-F-3)), (I-G), (I-Ga), (I-H) (e.g., (I-H-1), (I-H-2), or (I-H-3))) or Formula (II) (e.g., (II-a)), or a pharmaceutically acceptable salt thereof that induce degradation of a BCL-XL protein. These compounds are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions containing the compounds provided herein as well as methods of using and making the same. La présente divulgation concerne des composés de formule (I) (par exemple, (I-A) (par exemple, (I-A-1), (I-A-2) ou (I-A-3)), (I-B) (par exemple, (I-B-1), (I-B-2) ou (I-B-3)), (I-C), (I-D), (I-E) (par exemple, (I-E-1), (I-E-2) ou (I-E-3)), (I-Ea) (par exemple, (I-Ea-1), (I-Ea-2) ou (I-Ea-3)), (I-Eb) (par exemple, (I-Eb-1), (I-Eb-2) ou (I-Eb-3)), (I-F) (par exemple, (I-F-1), (I-F-2) ou (I-F-3)), (I-G), (I-Ga), (I-H) (par exemple, (I-H-1), (I-H-2) ou (I-H-3))) ou formule (II) (par exemple, (II-a)), ou un sel pharmaceutiquement acceptable de ceux-ci qui induisent la dégradation d'une protéine BCL-XL. Ces composés sont utiles, par exemple, pour traiter un cancer chez un sujet (par exemple, un être humain). La présente divulgation concerne également des compositions contenant les composés selon la divulgation ainsi que leurs procédés d'utilisation et de fabrication.